Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer.

Diagnostic cytopathology - 1 Dec 2010

Troncone Giancarlo, Malapelle Umberto, Cozzolino Immacolata, Palombini Lucio

Abstract excerpt

Recent evidences showed that metastatic colorectal cancer (CRC) patients with tumors harboring a KRAS gene mutation do not derive benefit from the administration of epidermal growth factor receptor-directed monoclonal antibodies. Typically, the specimens available for KRAS mutational analysis are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Codon
Share to Colorectal Neoplasms
Share to Cytological Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 20049979
DOI: 10.1002/dc.21302

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20049979-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer.PMID 20049979Read ↗

KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.Semantic proximity Read ↗

Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients.Semantic proximity Read ↗

Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.Semantic proximity Read ↗

Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists.Semantic proximity Read ↗

KRAS mutation testing in colorectal cancer.Semantic proximity Read ↗

KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.Semantic proximity Read ↗

KRAS mutation testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13.Semantic proximity Read ↗

Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers.Semantic proximity Read ↗

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.Semantic proximity Read ↗

KRAS testing on colo-rectal carcinoma cytological imprints.Semantic proximity Read ↗

Influence of mucinous and necrotic tissue in colorectal cancer samples on KRAS mutation analysis.Semantic proximity Read ↗

[Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.